financenews

Palatin’s Weight Loss Wonder Drug, PL7737, Gets Special FDA Nod for Obesity Caused by Leptin Receptor Deficiency: A Game Changer for Those Struggling with Rare Forms of Obesity

Exciting Developments in Melanocortin-4 Receptor Activators: Orphan Drug Designation Granted for PL7737 In a recent press release, Palatin Technologies, Inc., a pioneering biopharmaceutical company, announced that the US Food and Drug Administration (FDA) has granted orphan drug designation to PL7737, an innovative oral treatment that activates the melanocortin-4 receptor (MC4R). This designation is awarded to…

Read More

Soligenix’s Civax Booster Shows Rapid, Broad-Spectrum Protection Against COVID-19 Variants: New Study Published

Preclinical Efficacy of CiVax™: A New Approach to COVID-19 Vaccination Soligenix, Inc., a pioneering biopharmaceutical company, recently announced the publication of a study detailing the preclinical efficacy of CiVax™, a novel subunit vaccine against SARS-CoV-2. This single-dose vaccine, which is thermostabilized, is being developed as an alternative to the current two-shot mRNA vaccination series. Understanding…

Read More

Class Action Lawsuit Filed Against Arconic Corporation (ARNC): Shareholders Seek Compensation for Over $100 Million in Damages

Arconic Corporation Investors Suffering Losses Encouraged to Learn About Recovery Options New York, NY – If you are an investor in Arconic Corporation (NYSE: ARNC) and have suffered losses, you may be entitled to recover your losses under the federal securities laws. A securities class action lawsuit has been commenced against Arconic Corporation on behalf…

Read More

Seven Tech Giants Fueling the Stock Market Rally: Insights from Morgan Stanley (Not Tariffs)

Morgan Stanley CIO’s Perspective on Recent Market Weakness: Tariffs Aren’t the Culprit In a recent interview, Mike Wilson, the Chief Investment Officer (CIO) at Morgan Stanley, shared his insights on the recent market weakness and argued that it has little to do with tariffs. Wilson’s Analysis of the Market According to Wilson, the market’s decline…

Read More

John Hancock Multifactor Large Cap ETF (JHML): Why This Diversified Investment Option Deserves Your Attention

Exploring the John Hancock Multifactor Large Cap ETF (JHML): A Comprehensive Look If you’re intrigued by the Large Cap Blend segment of the US equity market and seeking broad exposure, consider the John Hancock Multifactor Large Cap ETF (JHML). Launched on September 28, 2015, this passively managed exchange-traded fund (ETF) provides investors with an effective…

Read More